BioSpace News Archive

CEL-SCI Corporation (NYSE American: CVM ), a Phase 3 cancer immunotherapy company, announced the closing of the offering of 1,000,000 shares of its common stock at a price of $14.65 per share, for total gross proceeds of $14.65 million, before deducting underwriting discounts and other offering expenses payable by the Company. Additionally, the Company has granted the underwriter a 30-day option to purchase up to 150,00

MTX110 Programmes to be Presented at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan (ISPNO 2020)

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 21st Annual New Ideas for the New Year Conference, which is being held virtually, on Wednesday, January 13, 2021. About Novanta Novanta is a leading global supplier of co

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 9,326,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,216,500 shares, at a public offering price of $37.00 per share. Th

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will host a live webcast presentation on Monday, December 14, 2020 at 8:00 a.m. ET to provide clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. The presentation will include upda

HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,910,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the pub

U.S. Government Exercises 1 st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate Total of 200 million doses ordered by the U.S government to date Additional doses ordered today will be delivered in Q2 2021 U.S. government retains option to purchase up to an additional 300 million doses

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 10, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering an aggregate of 3,000 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted o